Phapros Past Earnings Performance
Past criteria checks 0/6
Phapros's earnings have been declining at an average annual rate of -49.5%, while the Pharmaceuticals industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 0.8% per year. Phapros's return on equity is 0.8%, and it has net margins of 0.6%.
Key information
-49.5%
Earnings growth rate
-47.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.4% |
| Revenue growth rate | 0.8% |
| Return on equity | 0.8% |
| Net Margin | 0.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Phapros makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,014,130 | 5,959 | 402,399 | 0 |
| 30 Sep 23 | 1,071,955 | -4,208 | 430,298 | 0 |
| 30 Jun 23 | 1,157,882 | 24,676 | 435,080 | 0 |
| 31 Mar 23 | 1,160,189 | 27,179 | 425,713 | 0 |
| 31 Dec 22 | 1,168,474 | 28,070 | 426,831 | 0 |
| 30 Sep 22 | 1,160,700 | 17,310 | 416,375 | 0 |
| 30 Jun 22 | 1,150,713 | 11,787 | 420,560 | 0 |
| 31 Mar 22 | 1,095,413 | 9,516 | 413,151 | 0 |
| 31 Dec 21 | 1,051,444 | 11,071 | 387,697 | 0 |
| 30 Sep 21 | 1,047,460 | 9,361 | 398,666 | 0 |
| 30 Jun 21 | 992,870 | 32,033 | 397,020 | 0 |
| 31 Mar 21 | 976,479 | 69,478 | 404,191 | 0 |
| 31 Dec 20 | 980,557 | 48,488 | 393,571 | 0 |
| 30 Sep 20 | 1,013,758 | 92,050 | 401,188 | 0 |
| 30 Jun 20 | 1,007,235 | 81,161 | 388,460 | 0 |
| 31 Mar 20 | 1,156,943 | 83,113 | 432,102 | 0 |
| 31 Dec 19 | 1,105,420 | 102,034 | 422,520 | 0 |
| 30 Sep 19 | 1,117,743 | 96,573 | 413,733 | 0 |
| 30 Jun 19 | 1,167,715 | 127,344 | 420,162 | 0 |
| 31 Mar 19 | 1,060,784 | 124,930 | 382,756 | 0 |
| 31 Dec 18 | 1,022,970 | 132,307 | 369,528 | 0 |
| 30 Sep 18 | 1,058,665 | 148,930 | 369,780 | 0 |
| 31 Dec 17 | 1,002,126 | 125,266 | 364,314 | 0 |
| 31 Dec 16 | 816,133 | 87,002 | 312,879 | 0 |
Quality Earnings: PEHA has a large one-off gain of IDR27.8B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: PEHA's current net profit margins (0.6%) are lower than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PEHA's earnings have declined by 49.5% per year over the past 5 years.
Accelerating Growth: PEHA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PEHA had negative earnings growth (-78.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.8%).
Return on Equity
High ROE: PEHA's Return on Equity (0.8%) is considered low.